Tahoe Therapeutics Company Profile

Background

Tahoe Therapeutics, formerly known as Vevo Therapeutics, is a biotechnology company established in 2022 and headquartered in South San Francisco, California. The company is dedicated to revolutionizing drug discovery by integrating advanced artificial intelligence (AI) models with extensive in vivo data. Its mission is to develop superior drugs that cater to a broader patient demographic, with an initial focus on oncology.

Key Strategic Focus

Tahoe Therapeutics concentrates on:

In Vivo Data Generation: Utilizing the Mosaic platform to produce high-resolution in vivo data at scale, capturing phenotypic and transcriptomic changes in cell states to determine drug efficacy and gene expression changes.

AI-Driven Drug Discovery: Training AI models on gigascale single-cell maps to build virtual models of human cells, facilitating the identification of novel drug targets and candidates.

Oncology: Prioritizing the development of therapeutics for various solid tumor types, aiming to address unmet needs in cancer treatment.

Financials and Funding

In December 2022, Tahoe Therapeutics secured a $12 million seed funding round. Notable investors include:

General Catalyst

Wing Venture Capital

Mubadala Capital

Camford Capital

AIX Ventures

The capital is intended to advance the company's AI models and expand its in vivo data generation capabilities.

Pipeline Development

While specific pipeline candidates and clinical trial stages are not publicly disclosed, Tahoe Therapeutics is actively developing therapeutics targeting solid tumors. The company leverages its AI models and in vivo data to identify and validate novel drug targets, with the goal of progressing these candidates into clinical development.

Technological Platform and Innovation

Tahoe Therapeutics' innovation is anchored in:

Mosaic Platform: A proprietary system that generates high-resolution in vivo data at scale, capturing phenotypic and transcriptomic changes in cell states to determine drug efficacy and gene expression changes.

Tahoe-100M Dataset: The world's largest single-cell perturbation dataset, open-sourced to facilitate AI-driven drug discovery and the development of virtual cell models.

AI Models: Advanced AI models trained on gigascale single-cell maps to build virtual models of human cells, enabling the identification of novel drug targets and candidates.

Leadership Team

Nima Alidoust: CEO and Co-Founder. Previously served as Founding CEO and Advisor at Good Chemistry Company. Holds a Ph.D. in Computational and Quantum Chemistry from Princeton University.

Johnny Yu: Chief Scientific Officer and Co-Founder. Background in oncology and drug discovery research.

Michael Keiser: AI Scientist & Group Leader. Experience includes roles at UCSF, Stanford, CZI, and PGAFF.

Leadership Changes

In April 2025, the company rebranded from Vevo Therapeutics to Tahoe Therapeutics to better reflect its mission and avoid naming conflicts.

Competitor Profile

Market Insights and Dynamics

The biotechnology sector, particularly in AI-driven drug discovery, is experiencing significant growth. The integration of AI and in vivo data is transforming traditional drug development processes, leading to more efficient and targeted therapies.

Competitor Analysis

Partner Therapeutics: Focuses on developing and commercializing cancer medicines and combination therapies.

Verastem Oncology: Committed to developing new medicines to improve the lives of patients diagnosed with cancer.

Rakuten Medical: A clinical-stage biotechnology company developing tumor-targeted precision therapies.

Agenus: Specializes in immuno-oncology, focusing on the discovery and development of therapies for treating cancer.

Blueprint Medicines: A precision therapy company that invents medicines for people with cancer and blood disorders.

Karyopharm Therapeutics: A commercial-stage pharmaceutical company pioneering in cancer therapies.

Strategic Collaborations and Partnerships

Tahoe Therapeutics is actively seeking collaborations with top biopharmaceutical companies for large-scale drug, genetic, and phenotypic perturbation data generation deals. Additionally, the company is looking to co-develop or license over ten validated tumor-specific surface targets for various therapeutic modalities, including ADCs, BiTEs, radioligands, and TCR mimetics.

Operational Insights

Tahoe Therapeutics differentiates itself through its unique combination of scalable in vivo data generation and AI-driven analysis. This approach allows for a more comprehensive understanding of drug interactions within living organisms, setting the company apart from competitors that rely solely on in vitro data.